Biom-43. Somatictp53, Pik3R1, Nf1 Ortert Mutations Are Associated With Inferior Clinical Outcome In H3K27M-Altered Diffuse Midline Glioma: An International, Multi-Institutional Study
Thien Nguyen,Benjamin Lerman,Schuyler Stoller,Timothy Müller,Lion Comfort,Steven Leal-Ekman,Samantha Lyons,Lynette Holman,Calixito Hope Lucas Junior,Anu Banerjee,Alyssa Reddy,Nalin Gupta,Nicholas Whipple,Nicolas Gerber,Ana Stuecklin,Esha Areza,Rizo Marion,Truman Knowles,David Solomon,Andrea Franson,Carl Koschmann,Sonia Partap,Michelle Monje,Laura Prolo,Samuel Cheshier,Reuben Antony,Aashim Bhatia,Jessica Foster,Michael LaRiviere,Laura Maule,Andrea Webster Carrion,Cassie Kline,Sarah Bruningk,Javad Nazarian,Sebastian Waszak,Sabine Mueller
DOI: https://doi.org/10.1093/neuonc/noae165.0116
2024-11-29
Neuro-Oncology
Abstract:BACKGROUNDH3K27-altered diffuse midline gliomas (DMGs) have poor prognosis with no standard of care therapy beyond radiation (RT). While RT prolongs survival, not all patients respond. Molecular biomarkers can be a strategy to predict RT response and thus patient outcomes. METHODSWe performed a retrospective analysis of patients with biopsy-proven H3K27M-altered DMG between 2013-2023 from six US medical centers and the DMG Center in Zurich. Patients with tumor genomic sequencing and completion of RT were eligible. Genomic alterations were evaluated for somatic mutations, fusions, and chromosomal instability. Cox proportional hazard models were used to evaluate associations between genomic alterations and survival. Multivariate analysis included all significant variables at P <0.1 in initial analysis, including age at diagnosis, tumor location, TP53 and PIK3R1 alterations. RESULTS297 patients (135 female; median age 8.3 years; range 0.2-71.4 years) were included. Median progression-free survival (PFS) and overall survival (OS) was 7.6 months (95%CI: 6.9-8.6) and 14.0 months (95%CI: 12.9-15.7). In univariate analysis, TP53 or PIK3R1 status correlated with shorter OS (TP53 -mutant 12.5 vs. TP53 -wildtype 17.5 months; HR=1.5; 95%CI: (1.1-2.0), P= 0.005); ( PIK3R1- mutant 12.6 vs. 14.5 months; HR=1.9, 95%CI: (1.1-3.4), P = 0.03). Multivariate analysis corroborated TP53 -mutant status with poorer OS (HR=1.5; 95%CI: (1.2-2.0), P= 0.003). Subgroup univariate analysis of pontine DMG patients showed poorer OS with TP53, NF1, or TERT mutations ( TP53 -mutant 11.9 vs. 15.2 months; HR= 1.6; 95%CI: (1.1-2.3), P= 0.02); ( NF1- mutant 8.4 vs. 13.6 months; HR= 2.3; 95%CI: (1.1-5.0), P=0.03); ( TERT 8.5 vs. 13.6 months; HR= 2.5; 95%CI: (1.1-5.7), P= 0.03). Subsequent multivariate analysis corroborated the association of TERT mutations with poorer OS in pontine DMG (HR=2.5; 95%CI:1.05, 5.9, P= 0.03). CONCLUSIONSThis is the largest cohort of H3K27M-altered DMG patients with volumetric imaging analysis ongoing. Taken together, our data suggests these genetic alterations can risk-stratify patients for RT and future investigations of radiosensitizers targeting these alterations may improve survival.
oncology,clinical neurology